Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ABBV-105 alone or with upadacitinib in biologic DMARD-inadequate response rheumatoid arthritis
2018-000666-10Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elsubrutinib and upadacitinib in rheumatoid arthritis (RA) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline in disease activity score 28 using C-reactive protein at Week 12. Started Oct 2018; status: completed.
02
Drugs
elsubrutinibupadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-000666-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000666-10.